MedTrace Logo

A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome

NCT02968160 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2019-04-12

No results posted yet for this study

Summary

This is a Randomized, open-label, 2 groups, parallel design.

Conditions

  • Metabolic Syndrome

Interventions

DRUG

Telmisartan 40mg + Rosuvastatin 20mg

DRUG

Telmisartan 80mg + Rosuvastatin 20mg

DRUG

Telmisartan 40mg, 80 mg

DRUG

Rosuvastatin 20mg

Sponsors & Collaborators

  • Linical Korea

    collaborator INDUSTRY

  • Yuhan Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02968160 on ClinicalTrials.gov